Spero Therapeutics Inc (SPRO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.02-4.67%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · SPRO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
[/TABLE] Utebzi (tebipenem pivoxil) U.S. FDA Approval [TABLE] • | In June 2026, Spero and GSK announced that the U.S. Food and Drug Administration (FDA) approved Utebzi for the treatment of complicat…
Stated in 2 of 2 supplied quarters. Management reported: “The product is expected to be made available by GSK to U.S. patients by the end of 2026.” “GSK holds commercialization rights in the U.S. and Europe.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“[/TABLE] Utebzi (tebipenem pivoxil) U.S. FDA Approval [TABLE] • | In June 2026, Spero and GSK announced that the U.S. Food and Drug Administration (FDA) approved Utebzi for the treatment of complicat…”
““We continue to make solid progress on the tebipenem HBr program alongside our licensing partner, GSK, as we prepare for the FDA’s decision expected in June,” said Esther Rajavelu, President and CEO…”
“As we look to the remainder of 2026, our priorities are to advance SP001 toward a Phase 2 study in IgG4-related disease and continue evaluating additional development opportunities in immune-mediate…
Stated in 1 of 2 supplied quarters. Management reported: ““During the second quarter, we achieved several defining milestones that have fundamentally strengthened Spero’s business.” ““As we look to the remainder of 2026, our priorities are to advance SP001 toward a Phase 2 study in IgG4-related disease and continue evaluating additional development opportunities in immune-mediated diseases to expand the SP001 value proposition, while maintaining our disciplined approach to execution.”” Operating income was $-9.926 million in 2026-Q2.
““As we look to the remainder of 2026, our priorities are to advance SP001 toward a Phase 2 study in IgG4-related disease and continue evaluating additional development opportunities in immune-mediate…”
[/TABLE] [TABLE] • | The company expects that its cash and cash equivalents at June 30, 2026, together with the proceeds of the royalty financing, will be sufficient to fund operating expenses and ca…
Stated in 2 of 2 supplied quarters. Management reported: “This balance does not reflect the proceeds from the royalty financing completed in July 2026.” “We entered the quarter as a company preparing for an important regulatory milestone and have since then announced the FDA approval of Utebzi; a new Phase 2-ready immunology program with SP001; and financing that positions us to continue executing on our mission to deliver transformative therapies to patients,” said Esther Rajavelu, President and Chief Executive Officer of Spero.”
“[/TABLE] [TABLE] • | The company expects that its cash and cash equivalents at June 30, 2026, together with the proceeds of the royalty financing, will be sufficient to fund operating expenses and ca…”
“• Spero maintains its cash runway guidance into 2028.”
Sustain sufficient cash and cash equivalents to fund operating expenses and capital expenditures through 2028 and into the second half of 2029.
Focus on development and commercialization of tebipenem HBr, including leveraging FDA approval and licensing agreements.
Over the trailing year it converted 0.02x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 34% of the time over the next year (vs 53% for the rest of the cohort, n=2525).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
15 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.